Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
News|Articles|May 14, 2014
Equipment and Processing Report
- Equipment and Processing Report-05-21-2014
- Volume 0
- Issue 0
Advanced Aseptic Technology Provides Glass-Free Delivery of Injectable Drugs
Catalent's Advasept platform uses blow-fill-seal technology to aseptically manufacture, fill, and seal a polymeric primary container for injectable drugs.
Catalent Pharma Solutions launched its Advasept technology for the advanced aseptic filling of injectable drugs. The new platform provides a glass-free, aseptically filled, primary container that reduces or eliminates many concerns associated with traditional glass vials, including the potential for glass particulate contamination and the risk of accidental breakage in transit or use. Catalent uses blow-fill-seal manufacturing technology to aseptically manufacture, fill, and seal a polymeric primary container. Advasept stoppered vials are currently produced in 10-mL, 50-mL and 100-mL sizes and are available with pop-off or twist-off tops. Containers can be tailored to meet the unique needs of customers across many markets, such as biologics, pharmaceuticals, generics, and animal health.
Source:
Articles in this issue
over 12 years ago
Evaluating Facility cGMP Compliance By Reviewing Gowning Practicesover 12 years ago
Continuous Solid-Dosage Manufacturing Moves Forwardover 12 years ago
Packaging Innovations Displayed at INTERPHEX 2014over 12 years ago
System Improves Vial Drying and HandlingRelated to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
3
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
4
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
5